posted
I had to do some travelin for work yesterday but man nice runner... thought she'd lose some steam.... guess not!!! GL to all that are still in
Haha Lovethemarket.... sorry but this guy is out too But I have little regrets... I made over 100% so ya can't ever be upset about making money Moving on but I'll be watching for a dip if one happens that is
IP: Logged |
posted
If it dips big in the first 10 min. Monday I'm going back in BIG. I still can't believe I sold it on all that news the past week - I had no reason to - BUT if I didn't - it would probably be back to .90 now! LOL - but usually true!
Good Luck to us all! Rnjoy your weekend! Steve
IP: Logged |
posted
Love the Market, I'll also be watching this closely on Monday - I've been in and out a few times, got out way too early last time and hope to get back in if it dips. I think it's going to go up at least through H1N1 (swine) season this fall since Ygiene has a 100% kill rate for the virus.
-------------------- Taking care of my own money because no one else will treat it like their own!
IP: Logged |
posted
That's why I said it may see NASDAQ before we see .90 or $1.10 again! Could run to $10 - ONCY did a few years ago on the POSSIBILITY that one of their products could cure cancer. Went right back to 1.50-$2 range and it's STILL in the $2's. Who knows - but good luck to us all.
IP: Logged |
posted
This is SICK! I am SICK! (was out at $1.03 - trying to get back in at $1.10 - or is that $10.10??) Congrats to you smart (or ballzy) enough to hold. It's at $2.18 now...
IP: Logged |
posted
Don't underestimate the fear factor. BioNeutral and the Chertoff Group Announce a Collaborative Agreement to Continue Development of BioNeutral's Antimicrobial and Sterilant Technologies 8:29a ET August 31, 2009 (Business Wire) BioNeutral Group, Inc. (OTCBB: BONU) has expanded its relationship with the Chertoff Group (Washington, DC). Beginning September 1, 2009, two senior members of the Chertoff Group will provide dedicated strategic and operational advisory services to BioNeutral to enhance the company's strategic alliances, corporate operations, product testing, regulatory approvals, capital strategies and sales to the public and private sectors.
"It's exciting working with the Chertoff Group. We believe their collective talent, combined with BioNeutral's world class chemistry, will make a significant difference in saving lives presently lost to infection. We are proud to combine our efforts to help combat communicable diseases and make the hospital and all health care facilities a safer place," said Stephen J. Browand, President & CEO of BioNeutral Group.
"As some of the principal architects of homeland security policy and doctrine, our team has a good feel for how to examine problems from end-to-end, and how to evaluate technologies that might be brought to bear in solving those problems," said former Homeland Secretary Chertoff, Co-Founder and Chairman of the Chertoff Group. "By working with investors, private companies, governments and others who want to grow into homeland security markets, either organically or via acquisitions, I think our firm offers a unique value proposition and perspective. Given our deep knowledge of national and international biosecurity requirements in the commercial and government sectors alike, we are uniquely positioned to help BioNeutral in all aspects of the company's continuing growth."
Under terms of the Agreement, Chertoff Group Principal Jeffrey W. Runge, MD and Deputy Chief Operating Officer Dr. J. Bennet Waters will devote approximately half their time exclusively to advising BioNeutral. Dr. Runge will serve as Senior Medical Advisor, and Dr. Waters will serve as Senior Operations Advisor. Dr. Runge is formerly the Assistant Secretary of Health Affairs at the Department of Homeland Security (DHS); Dr. Waters is formerly Deputy Assistant Administrator at the Transportation Security Administration and served previously as Chief of Staff of DHS's Office of Health Affairs and as Counselor to two DHS Deputy Secretaries. In addition to Drs. Runge and Waters, other Chertoff Group principals will provide periodic support to BioNeutral regarding product testing and evaluation; acquisitions and procurement activities across commercial and federal targets; and capital-raising strategies.
"I believe BioNeutral's technology has the potential to be game-changing," said Chad Sweet, Co-Founder and Managing Principal at the Chertoff Group. "Based on preliminary data from independent lab testing, we are enthusiastic about the potential to instantly sterilize surfaces, fabric and skin without any known environmental effects. We believe BioNeutral's formulations have the potential to address several difficult problems facing the Nation, including influenza pandemics, national security threats such as anthrax, and in preventing expensive and dangerous hospital acquired infections."
Mr. Sweet previously served as the Chief of Staff of DHS and at the CIA. In addition to his expertise in security, he worked for twelve years in finance with Goldman Sachs and Morgan Stanley. At Chertoff Group, Mr. Sweet utilizes his unique background in intelligence, homeland security, and investment banking to advise companies and private equity firms expanding within the defense, aerospace, and security industries.
Other principals at Chertoff Group include General Michael Hayden, former Director of the Central Intelligence and National Security Agencies; former Homeland Security Deputy Secretary Paul Schneider (who previously served as head of acquisitions for the National Security Agency and United States Navy); and former Undersecretaries of Homeland Security Charles Allen and Rear Admiral Jay Cohen.
BioNeutral's relationship with Dr. Runge and Dr. Waters takes advantage of a unique skill set in homeland security and health care. Dr. Runge was DHS's first Chief Medical Officer, where he led the reorganization of biodefense operations into a new Office of Health Affairs. Prior to DHS, he was the head of the National Highway Traffic Safety Administration, where he instituted programs that led to the first absolute declines in U.S. motor vehicle deaths in nearly a decade and the lowest highway fatality rate in history. He has also been a board certified emergency physician for 25 years. Dr. Waters joined the Chertoff Group after three and a half years at the Department of Homeland Security (DHS), where his portfolio included intelligence and operational aspects of border and transportation security; immigration and customs enforcement activities; emergency management and the United States Secret Service. Prior to government service, Dr. Waters held senior strategic, financial and operations roles in early-stage organizations and turnaround situations.
"Dr. Waters and I are excited about the opportunity to deepen our relationship with BioNeutral," Dr. Runge said. "Over the past few months, we've gotten to know the company, its technology and its leadership team. We believe they are on the cutting edge of biotechnology, and we're looking forward to helping them take the next steps in developing, licensing and providing their unique formulations for the health and welfare of people."
ABOUT BIONEUTRAL GROUP
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene and Ogiene, which are eco-friendly and include natural and common ingredients found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.
The Chertoff Group is a security and risk management advisory firm that counsels corporate and government clients. The firm, which is based in Washington and has offices in New York City, is led by the former U.S. Secretary of Homeland Security Michael Chertoff and assists clients with addressing threats related to terrorism, biosecurity, fraud, cyber security, border protection, and supply chain security.
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene and are not yet available for sale in the United States.
Under the Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes", and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of BioNeutral Group can be found in the filings of BioNeutral Group with the U.S. Securities and Exchange Commission.
posted
Early this morning, it went like a rocket. I was not able to get in even at $1.90. I do not know if it will ever go dip today. Right now, it seems like a hot item at NASDAQ due to the swine flu effect.
IP: Logged |
posted
Hot-Pepper Thanks for your thread on BONU. I am so new I have no idea how much I still have to learn. It’s just my opinion, but this flu scare is going to get bigger. We are in a small, small rural area and they closed the schools in the spring for a week when this started. Sorry you didn’t get back in. I started so low I feel I can ride for a while. western acres - where the air is fresh and the people are friendly.
IP: Logged |
quote:Originally posted by Love the Market: This is SICK! I am SICK! (was out at $1.03 - trying to get back in at $1.10 - or is that $10.10??) Congrats to you smart (or ballzy) enough to hold. It's at $2.18 now...
HOLY $h**!!!! You're not kidding... I seriously thought she'd stop. The way I read it is it's just a decon product... It doesn't actually go into your body and kill H1N1.
I still haven't received a reply back from the company which kind of made my decision to get out last week. I also called Aimee (the one who is listed under IR contact) and when she answered the phone, "Hello" and started passing me around like a two bit you know what with lots of "ummms" I got a bad taste in my mouth...
As Love The Market stated... Congrats to the bawlzy ones
IP: Logged |
posted
Western Acres, Thank you for your compliments. There is a possibility that it will hit $5.00 before the week is out. Swine Flu thing is very serious and this company has the magic drug that kills the flu and or prevent people from being infected. At least that's what they have claim so far. I still will get in at a decent price when that opportunity presents itself. Good luck to you and keep riding with it. imo. Again do your own research before purchasing anything.
IP: Logged |
posted
Western Acres, Are you enjoying the fast ride. This performance is outstanding. I have seen it hit $2.44 today. As I indicated to you, by this week, it may reach $5.00 at the rate it is going. imo
IP: Logged |
posted
I just have to be a happy little pig on this one - from the $3K I made last week, but the "What COULD of been and ALMOST was" - like up $15K; is driving me NUTS....Would have wiped out all my losses over the past 6 years and even put me positive a little....
IP: Logged |
posted
MY GOSH! Talk about filling the gap! This has dropped $1.40 off HOD. MAybe we WILL be able to get back in - but I just spent all available on KKUR, SALN, and OPGX and 2 of 3 are down already a little. Oooops - BONU flying back up to $2.40's in like - 40 seconds! Damn.
IP: Logged |
posted
I guess BONU has been running too fast and too much in the shot time frame, therefore needs a breeder and some water to quench throat before continuation. imo
IP: Logged |
posted
Dropping like a rock - sure is getting that breather! I'll get back in if it gets back down near $1.00 (It's $1.77 now and still dropping...)
IP: Logged |
posted
Related Quotes Sym. Price Chg. BONU Trade News 1.635 0.125 BioNeutral Has Retained DC-Based Law Firm Hogan & Hartson to Manage Its EPA/FDA Regulatory Process
Sep 3, 2009 08:57:00 (ET)
NEWARK, N.J., Sep 03, 2009 (BUSINESS WIRE) -- BioNeutral Group, Inc. (BONU, Trade ) has retained Hogan and Hartson, one of Washington's oldest and most prestigious law firms, to manage its regulatory affairs as it proceeds through the approval process for its technology. Patrick Raher, a senior partner and the chairman of Hogan & Hartson's environmental practice, will serve as lead counsel for the BioNeutral Group.
BioNeutral is a publicly traded specialty life science company that is developing several product lines intended to neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses and spores. Some of its product applications (hard and soft surface sterilants and disinfectancts) will require certification by the Environmental Protection Agency (EPA); others (wound care, acne, sterilization of medical/surgical/dental instruments) will require approval by the Food and Drug Administration (FDA). Other product applications in the pipeline, such as stain removers, cleaners, and rust inhibitors are not regulated. Hogan & Hartson has decades of experience in helping clients achieve efficient certification and approvals in the Federal and state regulatory process.
With more than 1,100 lawyers practicing in 27 offices worldwide, Hogan & Hartson brings multiple practices and offices to bear to provide its clients with exceptional service and creative advice. Working at the intersection of business and government, both domestically and internationally, the firm helps its clients structure and complete their projects and transactions and guides them through the maze of government regulation. The firm also has special expertise in securing, protecting, and defending their clients' intellectual property.
"I have great confidence in Mr. Raher's and his team's professional ability," said Dr. Jeffrey Runge of Washington's Chertoff Group and BioNeutral's senior medical advisor. "As the former head of the National Highway Traffic Safety Administration, I had the opportunity to witness his firm's ability from the perspective of a Federal regulator. They have the highest integrity and clearly understand the regulatory process."
"We are extremely pleased to have this highly experienced and prestigious law firm join our group of platinum advisors to assist us in navigating the complexities of the regulatory process. This move will consolidate our various product registrations and is a key component to our overall business strategy," stated Stephen J. Browand, President & CEO of BioNeutral.
ABOUT BIONEUTRAL GROUP
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene and Ogiene, which are eco-friendly and include natural and common ingredients found in baby products and in every day foods. The Company has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers.
BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the Company's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene and are not yet available for sale in the United States.
Under the Private Securities Litigation Reform Act of 1995: The statements in the press release that relate to the Company's expectations with regard to the future impact on the Company's results from new products in development are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes", and words of similar import also identify forward-looking statements. Forward-looking statements are based on current facts and analyses and other information that are based on forecasts of future results, estimates of amounts not yet determined and assumptions of management. Readers are urged not to place undue reliance on the forward-looking statements, which speak only as of the date of this release. We assume no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Additional information on risks and other factors that may affect the business and financial results of BioNeutral Group can be found in the filings of BioNeutral Group with the U.S. Securities and Exchange Commission.
SOURCE: BioNeutral Group, Inc.
The Investor Relations Group Erika Moran/Tom Caden, 212-825-3210 or Public Relations: Laura Colontrelle, 212-825-3210
IP: Logged |
posted
This company by my research seem ligit. Will the quick sells taking profit crash it? I am in at 1.14 but its making nervous and a little is better than none.
IP: Logged |
posted
BONU picked up steam again this morning. The company is gearing towards NASDAQ once the approval process is complete and granted as per rumur. The big boys are geting their hands on it now. Hopefully it continues it's recovery path.
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
GL to all that are still in ![[Big Grin]](biggrin.gif)
![[Frown]](frown.gif)
But I have little regrets... ![[Wink]](wink.gif)
I made over 100% so ya can't ever be upset about making money 
